BioSpace News Archive

Cartessa Aesthetics recently launched its newest device, PHYSIQ, leading the demand for the latest advancement in body treatments. PHYSIQ is a novel, dual-modality system that offers deep heat to target tissue and electrical muscle stimulation (EMS) to re-educate muscle – all from one device and in one session.

Inventiva, a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, mucopolysaccharidoses and other diseases with significant unmet medical need, reported its cash position as of June 30, 2021 and its revenues for the first half of 20211.

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will present at the Canaccord Genuity 41st Annual Growth Conference, being held virtually on Wednesday, August 11, 2021 at 3:00 p.m. ET.

Align Technology, Inc., a leading global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad CAD/CAM software for digital orthodontics and restorative dentistry, reported financial results for the second quarter of fiscal 2021.

Histogen Inc., a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, announced that Histogen’s financial results for the second quarter will be released after the close of market on Wednesday, August 11, 2021.

Landing AI™ announced today a software licensing agreement with Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) to incorporate LandingLens™ into Ligand’s OmniAb® and xPloration™ antibody discovery platforms.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2021.

BioMarin Pharmaceutical Inc. announced financial results for the second quarter ended June 30, 2021.

Inovalon, a leading provider of cloud-based platforms empowering data-driven healthcare, announced financial results for the second quarter of 2021, issued guidance for the third quarter of 2021, and raised guidance for revenue growth and reaffirmed profitability guidance for full-year 2021.

The Board of Directors of Cigna Corporation declared a cash dividend of $1.00 per share of Cigna common stock, payable on September 23, 2021 to shareholders of record as of the close of business on September 8, 2021.